Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In Oncology, newer drugs largely compensated for sustained biosimilar erosion for off-patent drugs. Other areas, including Neuroscience and Haemophilia, also contributed healthily. However, 2023 guidance was weak, because of the declining COVID-19 business contribution. Now all eyes are on recently-approved drugs and late-stage pipeline candidates. Overal ....
